Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

CIPLA is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 3.957000
forwardPE 23.518774
debtToEquity 1.415000
earningsGrowth 0.037000
revenueGrowth 0.070000
grossMargins 0.665030
operatingMargins 0.214540
trailingEps 67.340000
forwardEps 63.540000

CIPLA's current ratio of 3.957 reflects its strong liquidity position. The company has enough cash reserves and current assets to service its short-term debt obligations, signaling that CIPLA is financially well-prepared to meet its liabilities without difficulty.
With Cipla Limited's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
Cipla Limited's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
Cipla Limited's forward EPS is less than its trailing EPS, signaling that the company's profitability is expected to shrink. This points to a potential downturn in earnings compared to last year.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

Over time, price projections for Cipla Limited have gradually risen, signaling growing optimism about the company's future. This upward revision reflects increasing confidence in Cipla Limited's ability to achieve strong financial results.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


The analysts' recent buy bias for CIPLA indicates strong confidence in the stock's future performance. This could encourage more investors to view CIPLA as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.